Related references
Note: Only part of the references are listed.Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis
Ji Yun Zheng et al.
CELL DEATH AND DIFFERENTIATION (2017)
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Jian Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks
F. Guo et al.
ONCOGENE (2016)
The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor
Michael Y. Choi et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies
Sara Sandri et al.
CANCER RESEARCH (2016)
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises
Cristina Bagacean et al.
IMMUNOTHERAPY (2016)
A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
Matthieu Broussas et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
Sheng-Bin Peng et al.
PLOS ONE (2016)
Initial therapy of chronic lymphocytic leukemia
Barbara Eichhorst et al.
SEMINARS IN ONCOLOGY (2016)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury
Yedidya Saiman et al.
HEPATOLOGY RESEARCH (2015)
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
Carolyn J. Owen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled et al.
CLINICAL CANCER RESEARCH (2014)
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky et al.
CLINICAL CANCER RESEARCH (2014)
Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies
Elisa ten Hacken et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Honokiol induces caspase-independent paraptosis via reactive oxygen species production that is accompanied by apoptosis in leukemia cells
Yao Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
Jan A. Burger et al.
BLOOD (2013)
BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
Michelle R. Kuhne et al.
CLINICAL CANCER RESEARCH (2013)
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44
Suping Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
Jennifer R. Brown
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
Jamie Honeychurch et al.
BLOOD (2012)
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments
Basile Stamatopoulos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4)
Shinya Oishi et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2012)
Advances in the assessment and control of the effector functions of therapeutic antibodies
Xu-Rong Jiang et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
Fabrizio Vianello et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy
L. Ysebaert et al.
LEUKEMIA (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
IgG2m4, an engineered antibody isotype with reduced Fc function
Zhiqiang An et al.
MABS (2009)
Human Protein Reference Database-2009 update
T. S. Keshava Prasad et al.
NUCLEIC ACIDS RESEARCH (2009)
The CXCR4 chemokine receptor in acute and chronic leukaemia:: a marrow homing receptor and potential therapeutic target
Jan A. Burger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference
JE Castro et al.
LEUKEMIA (2006)
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
JA Burger et al.
BLOOD (2006)
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
M Burger et al.
BLOOD (2005)
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
M Nishio et al.
BLOOD (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532
H El-Daly et al.
BLOOD (2005)
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
AP Mone et al.
BLOOD (2004)
Expression of the chemokine receptors CXCR4 and CCR7 and, disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
IM Ghobrial et al.
MAYO CLINIC PROCEEDINGS (2004)
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
CW Hendrix et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
LZ Rassenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The significance of cancer cell expression of the chemokine receptor CXCR4
F Balkwill
SEMINARS IN CANCER BIOLOGY (2004)
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
M Stanglmaier et al.
ANNALS OF HEMATOLOGY (2004)
Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions
L Egger et al.
CELL DEATH AND DIFFERENTIATION (2003)
Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia
N Tsukada et al.
BLOOD (2002)
Mitochondrial reactive oxygen species in cell death signaling
C Fleury et al.
BIOCHIMIE (2002)
Share Paper
